Abrasion particles affect classical signaling pathway of osteoclasts

doi:10.3877/cma.j.issn.1674-134X.2024.01.014

Abstract

Abstract:

Total joint replacement is one of the most successful treatments for end-stage osteoarthrosis. Although this method has achieved good results, the production of wear particles and the subsequent biological reaction which leads to aseptic prosthetic loosening, is still the most common cause of the failure of the total joint replacement. Signal pathway activation is one of the key factors causing osteolysis in prosthetic loosening. Therefore, inhibition of wear particles mediated signal pathway, osteoclast formation in treating osteoporosis and bony lesions, it is necessary to prevent bone loss. This review introduced the wear particles by several classic signaling pathways that affect osteoclast formation and related targets for activation or inhibition, local hypoxia by signaling pathways start autophagy affect osteoclast bone resorption, in order to delay or avoid the cause of aseptic loosening joints was renovated and patients to reduce the economic and psychological burden.

Key words: Signaling transduction, Osteoclasts, Prosthesis failure, Osteolysis

Fei Tan, Yongjie Qiao, Haoqiang Zhang, Kaipeng Zhuang, Jiankang Zeng, Jiahuan Li, Peijie Li, Dongdong Li, Jing Wang, Shenghu Zhou. Abrasion particles affect classical signaling pathway of osteoclasts[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(01): 106-117.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2024.01.014

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2024/V18/I01/106

Figures/Tables 3

References 72

[1]	Mehdipour S, Qoreishi M, Keipourfard A. Comparison of clinical, functional, and radiological outcomes of total knee arthroplasty using conventional and patient-specific instrumentation[J]. Arch Bone Jt Surg, 2020, 8(5): 625－632.
[2]	Sloan M, Premkumar A, ShethNP. Projected volume of primary total joint arthroplasty in the U．S., 2014 to 2030[J]. J Bone Joint Surg Am, 2018, 100(17): 1455－1460.
[3]	王坤正，田润，杨佩. 对我国关节置换外科未来发展的几点思考[J]. 中华创伤骨科杂志，2020, 22(7): 553－555.
[4]	van Dam PA, Verhoeven Y, Trinh XB, et al. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment[J]. Crit Rev Oncol Hematol, 2019, 133: 85－91.
[5]	Pennanen P, Kallionpää RA, Peltonen S, et al. Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player[J]. Mol Biol Rep, 2021, 48(2): 1243－1254.
[6]	Sharma AR, Jagga S, Chakraborty C, et al. Fibroblast-like-synoviocytes mediate secretion of pro-inflammatory cytokines via ERK and JNK MAPKs in Ti-particle-induced osteolysis[J/OL]. Materials, 2020, 13(16): 3628. DOI: 10.3390/ma13163628.
[7]	Jagga S, Sharma AR, Lee YH, et al. Sclerostin-mediated impaired osteogenesis by fibroblast-like synoviocytes in the particle-induced osteolysis model[J/OL]. Front Mol Biosci, 2021, 8: 666295. DOI: 10.3389/fmolb.2021.666295.
[8]	Cao X. RANKL-RANK signaling regulates osteoblast differentiation and bone formation[J/OL]. Bone Res, 2018, 6: 35. DOI: 10.1038/s41413-018-0040-9.
[9]	谢忠建. 从OPG-RANKL-RANK通路到骨质疏松症分子靶向治疗[J]. 中华骨质疏松和骨矿盐疾病杂志，2022, 15(2): 126－134.
[10]	刘鹏，邓亚鹏，曹国定，等. 人工关节置换术后假体无菌性松动的研究进展[J/CD]. 中华关节外科杂志(电子版), 2020, 14(3): 346－351.
[11]	Wang L, Gao Z, Zhang J, et al. Netrin-1 regulates ERK1/2 signaling pathway and autophagy activation in wear particle-induced osteoclastogenesis[J]. Cell Biol Int, 2021, 45(3): 612－622.
[12]	Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis[J]. Nature, 1999, 397(6717): 315－323.
[13]	Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification[J]. Genes Dev, 1998, 12(9): 1260－1268.
[14]	Xue JB, Zhan XL, Wang WJ, et al. OPG rs2073617 polymorphism is associated with upregulated OPG protein expression and an increased risk of intervertebral disc degeneration[J]. Exp Ther Med, 2016, 12(2): 702－710.
[15]	Gau YC, Yeh TJ, Hsu CM, et al. Pathogenesis and treatment of myeloma-related bone disease[J/OL]. Int J Mol Sci, 2022, 23(6): 3112. DOI: 10.3390/ijms23063112.
[16]	Guo YJ, PanWW, LiuSB, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020, 19(3): 1997－2007.
[17]	Koga Y, Tsurumaki H, Aoki-Saito H, et al. Roles of cyclic AMP response element binding activation in the ERK1/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production[J/OL]. Int J Mol Sci, 2019, 20(6): 1346. DOI: 10.3390/ijms20061346.
[18]	Park HB, Baek KH. E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers[J/OL]. Biochim Biophys Acta Rev Cancer, 2022, 1877(3): 188736. DOI: 10.1016/j.bbcan.2022.188736.
[19]	张晓非，吕震，王小泉，等. 人工关节假体周围无菌性松动的发生机制[J]. 天津医药，2020, 48(6): 572－576.
[20]	Wei CM, Su YJ, Qin X, et al. Monocrotaline suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced bone loss in vivo[J]. Cell Physiol Biochem, 2018, 48(2): 644－656.
[21]	Aashaq S, Batool A, Andrabi KI. TAK1 mediates convergence of cellular signals for death and survival[J]. Apoptosis, 2019, 24(1－2): 3－20.
[22]	Xu YR, Lei CQ. TAK1-TABs complex: acentral signalosome in inflammatory responses[J/OL]. Front Immunol, 2020, 11: 608976. DOI: 10.3389/fimmu.2020.608976.
[23]	Ha°land E, Moen IN, Veidal E, et al. TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan[J]. Oncotarget, 2021, 12(21): 2158－2168.
[24]	Ge C, Xiao G, Jiang D, et al. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development[J]. J Cell Biol, 2007, 176(5): 709－718.
[25]	Nam JS, Sharma AR, Jagga S, et al. Suppression of osteogenic activity by regulation of WNT and BMP signaling during titanium particle induced osteolysis[J]. J Biomed Mater Res A, 2017, 105(3): 912－926.
[27]	Yang S, Liu G. Targeting the ras/raf/MEK/ERK pathway in hepatocellular carcinoma[J]. Oncol Lett, 2017, 13(3): 1041－1047.
[28]	Li C, Wu Z, Yuan G, et al. Vx-11e protects against titanium-particle-induced osteolysis and osteoclastogenesis by supressing ERK activity[J]. Biochem Biophys Res Commun, 2019, 514(4): 1244－1250.
[29]	Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation[J]. Nature, 2003, 423(6937): 337－342.
[30]	O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease[J]. Immunity, 2012, 36(4): 542－550.
[31]	Zhou S, Dai Q, Huang X, et al. STAT3 is critical for skeletal development and bone homeostasis by regulating osteogenesis[J/OL]. Nat Commun, 2021, 12(1): 6891. DOI: 10.1038/s41467-021-27273-w.
[32]	Song F, Wei C, Zhou L, et al. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades[J]. J Cell Physiol, 2018, 233(2): 1723-1735.
[33]	Yu B, Bai J, Shi J, et al. miR-106b inhibition suppresses inflammatory bone destruction of wear debris-induced periprosthetic osteolysis in rats[J]. J Cell Mol Med, 2020, 24(13): 7490－7503.
[34]	Li HW, Zeng HS. Regulation of JAK/STAT signal pathway by miR-21 in the pathogenesis of juvenile idiopathic arthritis[J]. World J Pediatr, 2020, 16(5): 502－513.
[35]	Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression[J]. Cell, 2008, 133(3): 403－414.
[36]	Ghafouri-Fard S, Abak A, Shoorei H, et al. Regulatory role of microRNAs on PTEN signaling[J/OL]. Biomed Pharmacother, 2021, 133: 110986. DOI: 10.1016/j.biopha.2020.110986.
[37]	Li M, Luo R, Yang W, et al. miR-363-3p is activated by MYB and regulates osteoporosis pathogenesis via PTEN/PI3K/AKT signaling pathway[J]. In Vitro Cell Dev Biol Anim, 2019, 55(5): 376－386.
[38]	Lu K, Chen Q, Li M, et al. Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer[J]. Free Radic Biol Med, 2020, 159: 150－163.
[39]	Dorrello NV, Peschiaroli A, Guardavaccaro D, et al. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth[J]. Science, 2006, 314(5798): 467－471.
[40]	Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis[J]. Blood, 2011, 117(13): 3648－3657.
[41]	Zhang XY, Li HN, Chen F, et al. Icariin regulates miR-23a-3p-mediated osteogenic differentiation of BMSCs via BMP-2/Smad5/Runx2 and WNT/β-catenin pathways in osteonecrosis of the femoral head[J]. Saudi Pharm J, 2021, 29(12): 1405－1415.
[42]	蒋昇源，李丹，姜建浩，等. 假体无菌性松动过程中Co^2＋对成骨前体细胞的生物学反应[J]. 中国组织工程研究，2021, 25(21): 3292－3299.
[43]	Yang C, Liu W, Zhang X, et al. Naringin increases osteoprotegerin expression in fibroblasts from periprosthetic membrane by the Wnt/β-catenin signaling pathway[J/OL]. J Orthop Surg Res, 2020, 15(1): 600. DOI: 10.1186/s13018-020-02145-z.
[44]	Liu M, Li Y, Yang ST. Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells[J]. J Tissue Eng Regen Med, 2017, 11(1): 276－284.
[45]	Lv J, Sun X, Ma J, et al. Involvement of periostin-sclerostin-Wnt/β-catenin signaling pathway in the prevention of neurectomy-induced bone loss by naringin[J]. Biochem Biophys Res Commun, 2015, 468(4): 587－593.
[46]	王秋霏，顾叶，彭育沁，等. 人工假体磨损颗粒作用下Wnt/β-catenin信号通路对成骨细胞的影响[J]. 中国组织工程研究，2021, 25(24): 3894－3901.
[47]	陈检文，董立明，蒋科，等. 髋臼假体安装位置与无菌性松动的相关分析[J]. 中国矫形外科杂志，2022, 30(1): 28－32.
[48]	Yin J, Yin Z, Lai P, et al. Pyroptosis in periprosthetic osteolysis[J/OL]. Biomolecules, 2022, 12(12): 1733. DOI: 10.3390/biom12121733.
[49]	van Opdenbosch N, Lamkanfi M. Caspases in cell death, inflammation, and disease[J]. Immunity, 2019, 50(6): 1352－1364.
[50]	Bazrafkan M, Nikmehr B, Shahverdi A, et al. Lipid peroxidation and its role in the expression of NLRP1a and NLRP3genes in testicular tissue of male rats: a model of spinal cord injury[J]. Iran BiomedJ, 2018, 22(3): 151－159.
[51]	彭芃，傅媛，邱俊雄，等. RIPK3在磨损颗粒激活巨噬细胞PRRs/NLRP3信号通路引起人工关节无菌性松动中的作用机制[J]. 中国科学：生命科学，2020, 50(10): 1121－1131.
[52]	Ren H, Kong Y, Liu Z, et al. Selective NLRP3 (pyrin domain-containing protein 3) inflammasome inhibitor reduces brain injury after intracerebral hemorrhage[J]. Stroke, 2018, 49(1): 184－192.
[53]	Yang J, Wise L, Fukuchi KI. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer’s disease[J/OL]. Front Immunol, 2020, 11: 724. DOI: 10.3389/fimmu.2020.00724.
[54]	Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts[J]. J Bone Miner Res, 2013, 28(4): 711－722.
[55]	Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms[J]. Trends Endocrinol Metab, 2012, 23(11): 582－590.
[56]	Xing L, Carlson L, Story B, et al. Expression of either NF-kappa B p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption[J]. J Bone Miner Res, 2003, 18(2): 260－269.
[57]	Jämsen E, Pajarinen J, Kouri VP, et al. Tumor necrosis factor primes and metal particles activate the NLRP3 inflammasome in human primary macrophages[J]. Acta Biomater, 2020, 108: 347－357.
[58]	Ping Z, Wang Z, Shi J, et al. Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling[J]. Acta Biomater, 2017, 62: 362－371.
[59]	Gilbert W, Bragg R, Elmansi AM, et al. Stromal cell-derived factor-1 (CXCL12) and its role in bone and muscle biology[J/OL]. Cytokine, 2019, 123: 154783. DOI: 10.1016/j.cyto.2019.154783.
[60]	Drynda A, Singh G, Buchhorn GH, et al. Metallic wear debris may regulate CXCR4 expression in vitro and in vivo[J]. J Biomed Mater Res A, 2015, 103(6): 1940－1948.
[61]	Mizushima N, Levine B. Autophagy in human diseases[J]. N Engl J Med, 2020, 383(16): 1564－1576.
[62]	Margeta M. Autophagy defects in skeletal myopathies[J]. Annu Rev Pathol, 2020, 15: 261－285.
[63]	Hosokawa N, Hara T, Kaizuka T, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy[J]. Mol Biol Cell, 2009, 20(7): 1981－1991.
[64]	Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins[J]. Autophagy, 2010, 6(6): 764－776.
[65]	Lin HY, Ding JL, Peng YJ, et al. Proteomic and phosphoryproteomic investigations reveal that autophagy-related protein 1, a protein kinase for autophagy initiation, synchronously deploys phosphoregulation on the ubiquitin-like conjugation system in the mycopathogen Beauveria bassiana[J/OL]. mSystems, 2022, 7(1): e0146321. DOI: 10.1128/msystems.01463-21.
[66]	Weidberg H, Shpilka T, Shvets E, et al. LC3 and GATE-16 N termini mediate membrane fusion processes required for autophagosome biogenesis[J]. Dev Cell, 2011, 20(4): 444－454.
[67]	Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing[J]. EMBO J, 2000, 19(21): 5720－5728.
[68]	Camuzard O, Breuil V, Carle GF, et al. Autophagy involvement in aseptic loosening of arthroplasty components[J]. J Bone Joint Surg Am, 2019, 101(5): 466－472.
[69]	Wang J, Zhang Y, Cao J, et al. The role of autophagy in bone metabolism and clinical significance[J]. Autophagy, 2023, 19(9): 2409－2427.
[70]	Zhang Y, Cui Y, Wang L, et al. Autophagy promotes osteoclast podosome disassembly and cell motility athrough the interaction of kindlin3 with LC3[J/OL]. Cell Signal, 2020, 67: 109505. DOI: 10.1016/j.cellsig.2019.109505.
[71]	Zhang G, Wang Y, Tang G, et al. Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and-independent autophagic responses[J/OL]. BMC Complement Altern Med, 2019, 19(1): 269. DOI: 10.1186/s12906-019-2691-5.
[72]	Roy M, Roux S. Rab GTPases in osteoclastic bone resorption and autophagy[J/OL]. Int J Mol Sci, 2020, 21(20): 7655. DOI: 10.3390/ijms21207655.

Please choose a citation manager

Content to export